ArticleArchives of microbiology2026
Antimicrobial and antioxidant activities of Methylobacterium phyllosphaerae KS50439 isolated from Antarctic seawater.
Article in Archives of microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In this study, 85 marine microorganisms were isolated from Antarctic seawater, and their methanolic extracts were screened for antibacterial and antifungal activities against Escherichia coli DH5α, Staphylococcus aureus, and Candida albicans. Among the isolates, Methylobacterium phyllosphaerae KS50439 exhibited substantial antimicrobial activity. Biochemical characterization using API ZYM and API 20NE kits, together with phylogenetic analysis based on 16S ribosomal RNA gene sequencing, identified KS50439 as a unique strain. Growth curve analysis revealed that stationary-phase methanolic extracts exhibited stronger antibacterial and antifungal activities than extracts from other growth phases. Specifically, the extract showed half-maximal inhibitory concentration (IC₅₀) values of 2.47 ± 0.01 and 2.27 ± 0.03 mg/mL against E. coli DH5α and S. aureus, respectively, with corresponding minimum inhibitory concentration (MIC) values of 8.65 ± 0.07 and 8.54 ± 0.06 mg/mL. For C. albicans, the IC₅₀ and MIC values were 3.13 ± 0.02 and 9.09 ± 0.04 mg/mL, respectively. Antioxidant activity was assessed using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical scavenging assays. The scavenging activities were 73.80% (DPPH) and 87.62% (ABTS), with IC₅₀ values of 2.45 ± 0.08 and 0.12 ± 0.01 mg/mL, respectively. These findings demonstrate that extremophilic microorganisms, such as KS50439 adapt to harsh Antarctic environments and produce bioactive metabolites with notable antimicrobial and antioxidant potential. Collectively, these findings identify M. phyllosphaerae KS50439 as a promising source of bioactive compounds for biotechnological applications. Although further compound purification and safety evaluations are required before pharmaceutical or cosmetic applications can be considered, this study highlights the potential of polar microorganisms as valuable reservoirs of bioactive compounds.
Indexed as
Identifiers
42479215What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.